TABLE 1.

Clinical characteristics of 274 patients with MAC-LD according to treatment outcome^a

Characteristic	Values for patients with:			P value
	Total (n = 274)	Treatment success (n = 218)	Unfavorable response (n = 56)
Mean ± SD age (yr)	60.4 ± 11.0	60.2 ± 10.9	61.0 ± 11.7	0.647
No. (%) of patients >60 yr of age	139 (50.7)	111 (50.9)	28 (50.0)	0.903
No. (%) of patients by gender				0.002
Male	112 (40.9)	79 (36.2)	33 (58.9)
Female	162 (59.1)	139 (63.8)	23 (41.1)
Mean ± SD BMI	20.7 ± 3.0	20.6 ± 2.6	20.8 ± 4.5	0.717
No. (%) of patients with a BMI of ≤18.5 kg/m2	51 (18.6)	40 (18.3)	11 (19.6)	0.730
No. (%) of patients by smoking history				0.001
Nonsmoker	189 (69.0)	161 (73.9)	28 (50.0)
Current or former smoker	85 (31.0)	57 (26.1)	28 (50.0)
No. (%) of patients with a history of TB treatment	118 (43.1)	87 (39.9)	31 (55.4)	0.037
No. (%) of patients with a history of treatment for NTM lung disease	13 (4.7)	12 (5.5)	1 (1.8)	0.478
No. (%) of patients with the following comorbidities:
Chronic obstructive lung disease	32 (11.7)	26 (11.9)	6 (10.7)	0.801
Interstitial lung disease	24 (8.8)	17 (7.8)	7 (12.5)	0.267
Diabetes mellitus	24 (8.8)	16 (7.3)	8 (14.3)	0.101
Malignancy	49 (17.9)	34 (15.6)	15 (26.8)	0.051
No. (%) of patients with the following etiology:				0.153
Mycobacterium avium	126 (46.0)	105 (48.2)	21 (37.5)
Mycobacterium intracellulare	148 (54.0)	113 (51.8)	35 (62.5)
No. (%) of patients with a positive AFB smear at treatment initiation	118 (43.1)	82 (37.6)	36 (64.3)	<0.001
No. (%) of patients with the following type of disease:				0.820
Fibrocavitary	39 (14.2)	27 (12.4)	12 (21.4)
Nodular bronchiectatic	207 (75.5)	172 (78.9)	35 (62.5)
Unclassifiable	28 (10.2)	19 (8.7)	9 (16.1)
No. (%) of patients using an injectable aminoglycoside	137 (50.0)	103 (47.2)	34 (60.7)	0.072

^aBMI, body mass index; TB, tuberculosis; NTM, nontuberculous mycobacteria; AFB, acid-fast bacilli.